Clinical Trial · NCT05506566

68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Overview

As an emerging molecule targeting FAP, 68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-CHX in patients with various types of cancer and compared them with the results of 68Ga-FAPI-04 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-CHX.

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

Phase 1/2

Contacts

Weibing Miao, MD

miaoweibing@126.com

86-0591-87981618

Jie Zang, MD

15901495106@163.com

15901495106

ClinicalTrials.gov

NCT05506566

Drug / Compound

Isotope(s):
Target(s):